To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Xention Raises £8 Million in Private Equity Placement
Read time: 1 minute
XENTION LTD, the Cambridge-based biopharmaceutical company specializing in the discovery and development of ion channel-modulating drugs, has announced that it had closed an £8 million series D financing to fund the clinical development of Xention’s novel drugs for the treatment of atrial fibrillation.
The financing was led by new investor Seroba-Kernel Life Sciences Ltd and included existing investors Forbion Capital Partners, Crédit Agricole Private Equity, MVM and BTG International.
“We are very pleased to have attracted such a high-calibre new investor alongside our existing investors” commented Tim Brears, Xention’s Chief Executive. “We look forward to working closely with Seroba-Kernel and to making full use of their experience and expertise as we further develop our business and execute our strategy of focusing on the development of innovative drugs in the field of cardiac arrhythmia”.
Graham Fagg of Seroba-Kernel will join Xention’s Board of Directors. “As a new investor, we are very excited about the commercial opportunities afforded by Xention. In particular we recognize that Xention’s expertise in the discovery and development of drugs for atrial fibrillation is unrivalled. The company is led by an experienced management team and fits well within our portfolio of pioneering life science companies”.
Xention will use the funds to advance its programmes in atrial fibrillation to clinical proof of concept. The company’s interests in this area are focused on two key ion channel targets against which it has already developed a pipeline of selective, novel compounds that are in clinical and pre-clinical development.
“We have proven that our technology allows us to discover and develop drug candidates which act on ion channels, an important yet under-exploited class of targets.” said Tim Brears. “These funds will allow us to further develop and advance our programmes in atrial fibrillation, an area of substantial unmet medical need”.
The financing was led by new investor Seroba-Kernel Life Sciences Ltd and included existing investors Forbion Capital Partners, Crédit Agricole Private Equity, MVM and BTG International.
“We are very pleased to have attracted such a high-calibre new investor alongside our existing investors” commented Tim Brears, Xention’s Chief Executive. “We look forward to working closely with Seroba-Kernel and to making full use of their experience and expertise as we further develop our business and execute our strategy of focusing on the development of innovative drugs in the field of cardiac arrhythmia”.
Graham Fagg of Seroba-Kernel will join Xention’s Board of Directors. “As a new investor, we are very excited about the commercial opportunities afforded by Xention. In particular we recognize that Xention’s expertise in the discovery and development of drugs for atrial fibrillation is unrivalled. The company is led by an experienced management team and fits well within our portfolio of pioneering life science companies”.
Xention will use the funds to advance its programmes in atrial fibrillation to clinical proof of concept. The company’s interests in this area are focused on two key ion channel targets against which it has already developed a pipeline of selective, novel compounds that are in clinical and pre-clinical development.
“We have proven that our technology allows us to discover and develop drug candidates which act on ion channels, an important yet under-exploited class of targets.” said Tim Brears. “These funds will allow us to further develop and advance our programmes in atrial fibrillation, an area of substantial unmet medical need”.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
